2,014 results on '"Shyr, Yu"'
Search Results
52. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse
53. Functional data classification using covariate-adjusted subspace projection
54. Systematic Assessment of Small RNA Profiling in Human Extracellular Vesicles
55. Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
56. Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
57. Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
58. Supplementary Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
59. Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
60. Abstract 798: SeroNet Pooling Project of immunocompromised populations
61. Supplementary Table 1 from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
62. Data from ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
63. Data from TGF-β Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms
64. Supplemental Figure Legend from IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling
65. Supplemental Figures 1-7 from Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations
66. Data from Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations
67. Supplementary Figures 1-12, Tables 5-8, Methods from ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
68. Supplementary Table 1 from Loss of TGF-β Responsiveness in Prostate Stromal Cells Alters Chemokine Levels and Facilitates the Development of Mixed Osteoblastic/Osteolytic Bone Lesions
69. Supplementary Figure 4 from TGF-β Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms
70. Supplementary Tables 1 through 3 and Supplementary Figures 1 through 4 from Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
71. Supplementary Tables 1-4 from ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
72. Supplemental Tables 1-4 from Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations
73. Data from Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
74. Data from IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling
75. Supplementary figure 1 from IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling
76. Supplementary Figure 1 from TGF-β Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms
77. Supplementary Figure 3 from TGF-β Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms
78. Data from Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
79. Supplementary Figure 2 from TGF-β Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms
80. Supplementary Figure 2 from Loss of TGF-β Responsiveness in Prostate Stromal Cells Alters Chemokine Levels and Facilitates the Development of Mixed Osteoblastic/Osteolytic Bone Lesions
81. Supplementary Data from Transforming Growth Factor-β Signaling–Deficient Fibroblasts Enhance Hepatocyte Growth Factor Signaling in Mammary Carcinoma Cells to Promote Scattering and Invasion
82. Supplemental Figure Legends from Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations
83. Supplementary Data from Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
84. Supplementary Figure 1 from Loss of TGF-β Responsiveness in Prostate Stromal Cells Alters Chemokine Levels and Facilitates the Development of Mixed Osteoblastic/Osteolytic Bone Lesions
85. Induction of Frameshift and Base Pair Substitution Mutations by the Major DNA Adduct of the Endogenous Carcinogen Malondialdehyde
86. A peptide-retrieval strategy enables significant improvement of quantitative performance without compromising confidence of identification
87. Enhancement of Tumor Oxygenation and Radiation Response by the Allosteric Effector of Hemoglobin, RSR13
88. Casemix Adjustment of Managed Care Claims Data Using the Clinical Classification for Health Policy Research Method
89. Supplementary Methods from RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas
90. Table S5 from The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
91. Supplementary Figure 1 from Gene Expression Differences Associated with Human Papillomavirus Status in Head and Neck Squamous Cell Carcinoma
92. Supplementary Table from A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
93. Supplementary Figures 1-3, Tables 1-4 from Added Value of a Serum Proteomic Signature in the Diagnostic Evaluation of Lung Nodules
94. Supplementary Data from A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
95. Supplementary Tables S1-S10 from A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance
96. Data from A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
97. Data from RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas
98. Supplementary Figure from A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
99. Supplemental Figures from The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
100. Supplementary Table from Gene Expression Differences Associated with Human Papillomavirus Status in Head and Neck Squamous Cell Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.